NASDAQ:NKTR
Nektar Therapeutics Stock News
$1.76
-0.0450 (-2.50%)
At Close: May 17, 2024
Expert Ratings for Nektar Therapeutics
01:24pm, Monday, 18'th Apr 2022 Benzinga
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
1
3
1
0
L
Why Nektar Therapeutics Stock Is Crashing Today
11:30am, Monday, 18'th Apr 2022
The company is throwing in the towel on its lead pipeline program.
Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures
11:17am, Monday, 18'th Apr 2022
Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development prog
Nektar, Bristol Myers Squibb end clinical development of combination therapy including Opdivo
10:39am, Monday, 18'th Apr 2022
Shares of Nektar Therapeutics Inc. NKTR, -34.98% were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Mye
Nektar Therapeutics Stock Tanks Nearly 40%
09:48am, Monday, 18'th Apr 2022
Nektar Therapeutics is ending development of its cancer drug bempeg after the failure of two more trials of the drug in combination with Bristol Myers Squibb's Opdivo.
Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program
09:01am, Monday, 18'th Apr 2022
Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb Co (NYSE: BMY) have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.
Nektar stops clinical trials for key cancer drug, shares tumble
07:19pm, Thursday, 14'th Apr 2022
Nektar Therapeutics said on Thursday it had stopped all trials involving its key cancer drug following its failure in multiple studies, dragging the drug developer's shares down 23% in after-market tr
ProPhase Labs, Inc. (PRPH) Soars 11.2%: Is Further Upside Left in the Stock?
09:50am, Tuesday, 05'th Apr 2022 Zacks Investment Research
ProPhase Labs, Inc. (PRPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more
Why Is Nektar (NKTR) Down 47.6% Since Last Earnings Report?
03:30pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Nektar (NKTR) Down 47.6% Since Last Earnings Report?
12:47pm, Wednesday, 30'th Mar 2022
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More
04:32pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Pipeline and regulatory updates from Nektar (NKTR) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
What 4 Analyst Ratings Have To Say About Nektar Therapeutics
08:22pm, Tuesday, 15'th Mar 2022 Benzinga
Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ:NKTR) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
2
1
What 4 Analyst Ratings Have To Say About Nektar Therapeutics
08:22pm, Tuesday, 15'th Mar 2022 Benzinga
Analysts have provided the following ratings for Nektar Therapeutics (NASDAQ: NKTR ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 Last 30D 0 0 2 0 0 1M Ago 0 1 0 1 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Nektar Therapeutics has an average price target of $10.5 with a high of $21.00 and a low of $6.00. Below is a summary of how these 4 analysts rated Nektar Therapeutics over the past 3 months. The greater the number of bullish ratings, the … Full story available on Benzinga.com
Where Nektar Therapeutics Stands With Analysts
06:02pm, Tuesday, 15'th Mar 2022 Benzinga
Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
2
1
0
L
Where Nektar Therapeutics Stands With Analysts
06:02pm, Tuesday, 15'th Mar 2022 Benzinga
Nektar Therapeutics (NASDAQ: NKTR ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 1 0 Last 30D 0 0 2 0 0 1M Ago 0 1 0 1 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $10.5 versus the current price of Nektar Therapeutics at $4.285, implying upside. Below is a summary of how these 4 analysts rated Nektar Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the … Full story available on Benzinga.com